Matinas BioPharma Holdings, Inc. (MTNB) Starts Presentation at NobleCon13
Matinas BioPharma Holdings (OTC: MTNB) is a clinical-stage biopharmaceutical company, focuses on identifying and developing therapeutics for the treatment of fungal and bacterial infections. The company develops orally delivered therapeutics based on a proprietary, lipid crystal drug delivery platform called cochleate delivery technology. Its lead product candidate is MAT 2203, an oral formulation of the broad spectrum anti-fungal drug amphotericin B that is in Phase II study for the treatment of fungal infections. For more information, visit the company’s website at www.matinasbiopharma.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of…







